Greenleaf Trust’s Abiomed Inc ABMD Stock Holding History

Greenleaf Trust’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-488	Closed	-$219K	–	565
2018 Q3	$219K	Buy	+488	New	+$192K	﹤0.01%	481

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Greenleaf Trust's ABMD Position: Q4 2018 in Review

Greenleaf Trust sold out of Abiomed Inc (ABMD) in Q4 2018, closing a stake of 488 shares — an estimated $219K sold.

Greenleaf Trust first reported a position in ABMD in Q3 2018 and held it in 1 quarter. The position peaked at $219K in Q3 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q4 2018.

Greenleaf Trust reported no remaining Abiomed Inc position as of Q4 2018 after selling out during the quarter.
Greenleaf Trust sold 488 Abiomed Inc shares in Q4 2018, an estimated $219K.
Greenleaf Trust first reported a position in Abiomed Inc in Q3 2018 and held it in 1 quarter.
Greenleaf Trust's Abiomed Inc position peaked at $219K in Q3 2018.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2018.

Based on Greenleaf Trust's 13F filing for Q4 2018, filed 7 Feb 2019.